Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Roche Holding AG (ROG.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
355.80-2.00 (-0.56%)
At close: 5:31PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close357.80
Open357.80
Bid0.00 x 0
Ask0.00 x 0
Day's Range353.45 - 359.05
52 Week Range290.55 - 374.70
Volume838,892
Avg. Volume1,084,422
Market Cap309.834B
Beta (5Y Monthly)0.29
PE Ratio (TTM)21.91
EPS (TTM)16.24
Earnings DateJul 22, 2021
Forward Dividend & Yield9.10 (2.56%)
Ex-Dividend DateMar 18, 2021
1y Target Est378.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ROG.SW

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Motley Fool

      Why Atea Pharmaceuticals Stock Got Crushed This Week

      Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence. The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-527, badly missed the mark in a phase 2 trial called MOONSONG for patients with mild or moderate cases of COVID-19. AT-527 is being co-developed with pharma heavyweight Roche (OTC: RHHBY).

    • Reuters

      UPDATE 3-Roche's implant for chronic eye disorder wins U.S. approval

      Roche Holding AG on Friday won approval from the U.S. health regulator for its eye implant to treat a chronic disorder causing blurred vision, giving patients an alternative to receiving monthly eye injections with existing treatments. The surgically implantable device Susvimo is intended to treat wet age-related macular degeneration (wet AMD), a disorder caused by the leak of fluid or blood from abnormal blood vessels into an area near the retina called the macula. Anti-VEGF therapies, the current standard of care for wet AMD, work against a protein said to play a key role in the disease.

    • Reuters

      Roche's implant for chronic eye disorder wins U.S. approval

      (Reuters) -Roche Holding AG on Friday won approval from the U.S. health regulator for its eye implant to treat a chronic disorder causing blurred vision, giving patients an alternative to receiving monthly eye injections with existing treatments. The surgically implantable device Susvimo is intended to treat wet age-related macular degeneration (wet AMD), a disorder caused by the leak of fluid or blood from abnormal blood vessels into an area near the retina called the macula. The device is designed to continuously deliver a customized version of the Swiss company's drug ranibizumab, branded as Lucentis, which is an anti-vascular endothelial growth factor (anti-VEGF) therapy.

    Advertisement
    Advertisement